Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Intelligent cancer therapy with synthetic biology methods

Description du projet

Une approche innovante pour lutter contre le cancer via des circuits synthétiques

Bien que l’immunothérapie fasse partie intégrante du traitement de certains types de cancer depuis les dernières décennies, la chirurgie, la radiothérapie ou la chimiothérapie, seules ou en combinaison, demeurent les interventions les plus courantes. Le projet InCanTeSiMo, financé par l’UE, vise à lutter contre le cancer via l’administration et l’activation locale de circuits synthétiques dotés d’une action d’éradication du cancer. Les circuits synthétiques détecteront l’état de la cellule dans laquelle ils sont administrés et agiront uniquement s’ils détectent un état pathologique. Cette thérapie innovante contre le cancer peut être adaptée à chaque patient spécifique lors de la conception des circuits synthétiques.

Objectif

With InCanTeSiMo I aim to realize local delivery and activation of cancer-defeating synthetic circuits. Despite the advent of immunotherapy as promising treatment against a number of cancers, surgery, radio- or chemotherapy, alone or in combination, remain the most common interventions. While surgery and radiotherapy are mainly targeted to the cancer itself, chemotherapy has a systemic mode of action, affecting both healthy as well as diseased cells. An innovative way to fight cancer would be the use of synthetic circuits sensing the status of the cell into which they are delivered and acting only in response to a detected diseased status. This type of cancer therapy lends itself well to personalization, as each patient’s specific profile could be considered when designing the synthetic circuits. Since naked plasmid DNA cannot be simply released in the blood, the synthetic circuits must be encapsulated into protective vehicles, which should shield them from the immune system and accumulate them at the site of cancer. Moreover, to limit side effects due to the potential accumulation of the delivery vehicles in other body parts, it would be advantageous to locally activate the synthetic circuits with an external trigger, such as light. This would additionally allow activating the therapy at specific time points. This project comprises three major engineering efforts: 1) the establishment of cost-effective production of delivery vehicles able to specifically invade cancer cells; 2) the realization of new synthetic circuits functioning at the protein level that discern between healthy and cancer cells based on the amount of a metabolite and trigger apoptosis, or convert a pro-drug into the active drug, in the latter ones only; 3) the development of a novel red light-inducible protein-protein interaction tool.

Régime de financement

ERC-COG - Consolidator Grant

Institution d’accueil

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG
Contribution nette de l'UE
€ 2 000 000,00
Adresse
FAHNENBERGPLATZ
79098 Freiburg
Allemagne

Voir sur la carte

Région
Baden-Württemberg Freiburg Freiburg im Breisgau, Stadtkreis
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 2 000 000,00

Bénéficiaires (1)